tiprankstipranks
Alnylam Pharmaceuticals (CH:DUL)
NASDAQ:DUL
Switzerland Market
DUL
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (DUL) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

DUL Analyst Ratings

Strong Buy
19Ratings
Strong Buy
17 Buy
2 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DUL Stock 12 Month Forecast

Average Price Target

CHF368.54
Based on 19 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is CHF368.54 with a high forecast of CHF444.45 and a low forecast of CHF298.99. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"227":"CHF227","336":"CHF336","445":"CHF445","281.5":"CHF281.5","390.5":"CHF390.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":444.44660150000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF444.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":368.5405091953333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF368.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":298.99135010000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF298.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[227,281.5,336,390.5,445],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.981,245.55527703846153,262.12955407692306,278.7038311153846,295.2781081538462,311.8523851923077,328.42666223076924,345.0009392692308,361.57521630769236,378.14949334615386,394.7237703846154,411.2980474230769,427.8723244615385,{"y":444.44660150000004,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.981,239.7163468611795,250.45169372235895,261.1870405835384,271.9223874447179,282.6577343058974,293.3930811670769,304.1284280282564,314.8637748894359,325.5991217506154,336.3344686117948,347.0698154729743,357.8051623341538,{"y":368.5405091953333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.981,234.36641154615384,239.7518230923077,245.13723463846154,250.52264618461538,255.90805773076923,261.2934692769231,266.67888082307695,272.06429236923077,277.44970391538465,282.83511546153846,288.22052700769234,293.60593855384616,{"y":298.99135010000003,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":228.981,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF444.45Average Price TargetCHF368.54Lowest Price TargetCHF298.99
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:DUL
Eliana Merle
Barclays
Barclays
CHF425.86
Buy
―
Reiterated
06/22/26
Barclays Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Oppenheimer Analyst forecast on CH:DUL
Kostas Biliouris
Oppenheimer
Oppenheimer
CHF404.04
Buy
―
Reiterated
06/22/26
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Coherus Biosciences (CHRS)
RBC Capital Analyst forecast on CH:DUL
Luca Issi
RBC Capital
RBC Capital
CHF359.6
Buy
―
Reiterated
06/18/26
RBC Capital Remains a Buy on Alnylam Pharma (ALNY)
J.P. Morgan Analyst forecast on CH:DUL
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX) and Alnylam Pharma (NASDAQ: ALNY)
Morgan Stanley Analyst forecast on CH:DUL
Michael Ulz
Morgan Stanley
Morgan Stanley
CHF298.99
Hold
―
Reiterated
06/12/26
Alnylam: Hold Rating Reaffirmed as TTR Franchise Growth Offsets Slight Sales Shortfall; $370 Price Target Unchanged
H.C. Wainwright Analyst forecast on CH:DUL
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
CHF412.12
Buy
―
Reiterated
06/05/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Fractyl Health, Inc. (NASDAQ: GUTS)
Citi Analyst forecast on CH:DUL
Eric Joseph
Citi
Citi
CHF307.07
Buy
―
Initiated
05/19/26
Alnylam initiated with a Buy at CitiAlnylam initiated with a Buy at Citi
Canaccord Genuity Analyst forecast on CH:DUL
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF346.67
Buy
―
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT), The Ensign Group (NASDAQ: ENSG) and Alnylam Pharma (NASDAQ: ALNY)
Evercore ISI Analyst forecast on CH:DUL
Cory Kasimov
Evercore ISI
Evercore ISI
CHF323.23
Buy
―
Reiterated
05/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Alnylam Pharma (NASDAQ: ALNY) and The Ensign Group (NASDAQ: ENSG)
Truist Financial Analyst forecast on CH:DUL
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
Raymond James Analyst forecast on CH:DUL
Tiago Fauth
Raymond James
Raymond James
CHF303.84→CHF304.65
Hold
―
Reiterated
05/01/26
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on CH:DUL
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF395.15
Buy
―
Reiterated
05/01/26
Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Chardan Capital Analyst forecast on CH:DUL
Keay Nakae
Chardan Capital
Chardan Capital
CHF343.44
Buy
―
Reiterated
05/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on CH:DUL
William Pickering
Bernstein
Bernstein
CHF362.02→CHF361.21
Buy
―
Reiterated
05/01/26
Alnylam Pharma (ALNY) Gets a Buy from Bernstein
TD Cowen Analyst forecast on CH:DUL
Ritu Baral
TD Cowen
TD Cowen
CHF389.5
Buy
―
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Alignment Healthcare (NASDAQ: ALHC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:DUL
Eliana Merle
Barclays
Barclays
CHF425.86
Buy
―
Reiterated
06/22/26
Barclays Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Oppenheimer Analyst forecast on CH:DUL
Kostas Biliouris
Oppenheimer
Oppenheimer
CHF404.04
Buy
―
Reiterated
06/22/26
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Coherus Biosciences (CHRS)
RBC Capital Analyst forecast on CH:DUL
Luca Issi
RBC Capital
RBC Capital
CHF359.6
Buy
―
Reiterated
06/18/26
RBC Capital Remains a Buy on Alnylam Pharma (ALNY)
J.P. Morgan Analyst forecast on CH:DUL
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX) and Alnylam Pharma (NASDAQ: ALNY)
Morgan Stanley Analyst forecast on CH:DUL
Michael Ulz
Morgan Stanley
Morgan Stanley
CHF298.99
Hold
―
Reiterated
06/12/26
Alnylam: Hold Rating Reaffirmed as TTR Franchise Growth Offsets Slight Sales Shortfall; $370 Price Target Unchanged
H.C. Wainwright Analyst forecast on CH:DUL
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
CHF412.12
Buy
―
Reiterated
06/05/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Fractyl Health, Inc. (NASDAQ: GUTS)
Citi Analyst forecast on CH:DUL
Eric Joseph
Citi
Citi
CHF307.07
Buy
―
Initiated
05/19/26
Alnylam initiated with a Buy at CitiAlnylam initiated with a Buy at Citi
Canaccord Genuity Analyst forecast on CH:DUL
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF346.67
Buy
―
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT), The Ensign Group (NASDAQ: ENSG) and Alnylam Pharma (NASDAQ: ALNY)
Evercore ISI Analyst forecast on CH:DUL
Cory Kasimov
Evercore ISI
Evercore ISI
CHF323.23
Buy
―
Reiterated
05/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Alnylam Pharma (NASDAQ: ALNY) and The Ensign Group (NASDAQ: ENSG)
Truist Financial Analyst forecast on CH:DUL
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
Raymond James Analyst forecast on CH:DUL
Tiago Fauth
Raymond James
Raymond James
CHF303.84→CHF304.65
Hold
―
Reiterated
05/01/26
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on CH:DUL
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF395.15
Buy
―
Reiterated
05/01/26
Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Chardan Capital Analyst forecast on CH:DUL
Keay Nakae
Chardan Capital
Chardan Capital
CHF343.44
Buy
―
Reiterated
05/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on CH:DUL
William Pickering
Bernstein
Bernstein
CHF362.02→CHF361.21
Buy
―
Reiterated
05/01/26
Alnylam Pharma (ALNY) Gets a Buy from Bernstein
TD Cowen Analyst forecast on CH:DUL
Ritu Baral
TD Cowen
TD Cowen
CHF389.5
Buy
―
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Alignment Healthcare (NASDAQ: ALHC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months
Keay NakaeChardan Capital
Success Rate
25/40 ratings generated profit
63%
Average Return
+6.25%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +6.25% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
19/26 ratings generated profit
73%
Average Return
+29.54%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +29.54% per trade.
2 Years
Keay NakaeChardan Capital
Success Rate
32/40 ratings generated profit
80%
Average Return
+39.72%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +39.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DUL Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
11
16
20
19
18
Buy
28
32
19
17
11
Hold
9
10
6
7
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
58
45
43
33
In the current month, DUL has received 29 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. DUL average Analyst price target in the past 3 months is 368.54.
Each month's total comprises the sum of three months' worth of ratings.

DUL Financial Forecast

DUL Earnings Forecast

Next quarter’s earnings estimate for DUL is CHF1.31 with a range of CHF0.81 to CHF1.75. The previous quarter’s EPS was CHF1.22. DUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.
Next quarter’s earnings estimate for DUL is CHF1.31 with a range of CHF0.81 to CHF1.75. The previous quarter’s EPS was CHF1.22. DUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Sales Forecast

Next quarter’s sales forecast for DUL is CHF1.07B with a range of CHF983.44M to CHF1.15B. The previous quarter’s sales results were CHF943.18M. DUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.
Next quarter’s sales forecast for DUL is CHF1.07B with a range of CHF983.44M to CHF1.15B. The previous quarter’s sales results were CHF943.18M. DUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Stock Forecast FAQ

What is CH:DUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 368.54.
    What is CH:DUL’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:DUL, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
        Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Alnylam Pharmaceuticals’s share price target?
          The average share price target for Alnylam Pharmaceuticals is 368.54. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF444.45 ,and the lowest forecast is CHF298.99. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Alnylam Pharmaceuticals?
            Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
              How can I buy shares of Alnylam Pharmaceuticals?
              To buy shares of CH:DUL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.